NEW YORK (GenomeWeb News) – Adaptive Biotechnologies said today that it has inked a biomarker discovery agreement with Janssen Research & Development.

Under the terms of the agreement, which was facilitated by the Johnson & Johnson Innovation Center, Adaptive will use its targeted next-gen sequencing-based ImmunoSeq assay to study immune response to diseases in order to identify patients more likely to respond to immunology and oncology drugs being developed by Janssen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.